Cory Ahonen
Corporate Officer/Principal presso ImmuRx, Inc.
Provenienza dei contatti di primo grado di Cory Ahonen
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
ImmuRx, Inc.
ImmuRx, Inc. BiotechnologyHealth Technology ImmuRx, Inc. develops adjuvant platforms for the treatment of cancer and infectious disease. Its product includes CD40 compound, an antibody. The company was founded by Randolph J. Noelle and Ross Kedl in 2005 and is headquartered in Lebanon, NH.
6
| Private Company | Biotechnology | 6 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Cory Ahonen tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
Serenex, Inc.
Serenex, Inc. Pharmaceuticals: MajorHealth Technology Serenex, Inc. operates as a biotechnology company that develops drugs for tumors and cancers of the blood and bone marrow. Its products include drugs for chemotherapy treatments as well as inhibitor compounds. Serenex was founded by George Young and Timothy Haystead in 2000 and is headquartered in Durham, NC. | Pharmaceuticals: Major | Founder | |
Waratah Pharmaceuticals, Inc.
Waratah Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Part of OPKO Health, Inc., Waratah Pharmaceuticals, Inc. develops pharmaceutical products. The company is based in Calgary, Canada. The Canadian company was founded by Susan Dana Jones. Waratah Pharmaceuticals was acquired by Transition Therapeutics, Inc., part of OPKO Health, Inc. from September 01, 2016 on January 28, 2002 for $15.46 million. | Medical Specialties | Founder | |
Gene Solutions LLC
Gene Solutions LLC BiotechnologyHealth Technology Gene Solutions LLC conducts therapeutic drug discovery research for central nervous system diseases by utilizing its proprietary mitochondrial genomic targets. It delivers mitochondrial therapeutic solutions and choices for pharmaceutical and biotechnology companies to enhance their drug pipelines in the field of Alzheimer’s, Parkinson’s, and schizophrenia diseases. The company was founded in 2006 by William Davis Parker Jr. and Edward P Connell and is headquartered in Charlottesville, VA. | Biotechnology | Director/Board Member | |
Dartmouth College | College/University | Undergraduate Degree | |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Undergraduate Degree | |
Massachusetts Institute of Technology | College/University | Graduate Degree | |
The University of California, San Francisco | College/University | Doctorate Degree | |
MIST, Inc.
MIST, Inc. Miscellaneous Commercial ServicesCommercial Services MIST, Inc. is a private company that specializes in the installation, revamp, and routine maintenance of tower internals. The company is based in Pleasant Plain, OH. The company provides an efficient union workforce devoted to safety and successful project completion. The company is committed to teamwork, honesty, hard work, determination, and responsibility. The company has experience working with various industries such as oil refineries, chemical plants, steel mills, and breweries. MIST has recently partnered with Sitedocs to upload all of their safety forms into their platform, making the transition into the digital age. | Miscellaneous Commercial Services | President | |
HARPOON THERAPEUTICS, INC. | Biotechnology | Corporate Officer/Principal | |
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer |
Statistiche
Distribuzione geografica
Stati Uniti | 11 |
Canada | 2 |
Settori
Health Technology | 5 |
Consumer Services | 4 |
Commercial Services | 4 |
Finance | 2 |
Posizioni
Chief Tech/Sci/R&D Officer | 5 |
Founder | 4 |
Corporate Officer/Principal | 4 |
Undergraduate Degree | 2 |
Chief Executive Officer | 1 |
Contatti più connessi
Insiders | |
---|---|
Susan Jones | 9 |
David DeLucia | 4 |
Robin Teskin | 2 |
Randolph J. Noelle | 1 |
Ross Kedl | 1 |
Marc Ernstoff | 1 |
- Borsa valori
- Insiders
- Cory Ahonen
- Connessioni Società